Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
MyoKardia and LianBio have entered into a strategic collaboration to develop and commercialize mavacamten in China and other Asian territories.
read more
Tuesday, February 28, 2017
Myoderm, a global clinical trial supply company has announced the opening of their new UK headquarters. This clinical storage and distribution facility was strategically developed in response to ongoing challenges in the clinical trial industry, ...
read more
Monday, February 06, 2017
Myoderm has announced the addition of Chief Operating Officer James Lovett. James will work alongside long-time Managing Director Michael Cohen to lead the company on a continued path of growth and global expansion.
read more
Friday, November 06, 2020
Mylan and Pfizer announced the FTC accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.
read more
Monday, September 21, 2020
Mylan and Pfizer announced the companies have received final approval from the EC for the proposed combination of Mylan and Pfizer's Upjohn business.
read more
Monday, November 18, 2019
Mylan and Pfizer announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris.
read more
Mylan and Lupin announced that the EC has granted marketing authorization for Nepexto, a biosimilar to Enbrel.
read more
Wednesday, April 29, 2020
Mylan and Biocon announced the launch of Fulphila®, a biosimilar to Neulasta® (pegfilgrastim). Fulphila is approved by Health Canada.
read more
Mylan and Biocon announced the FDA has approved the NDA for Semglee in vial and pre-filled pen presentations, to control high blood sugar.
read more
Monday, December 04, 2017
Mylan and Aspen announced the U.S. launch of Myleran Injection, 60 mg/10 mL (6 mg/mL) Single-dose Vial, a generic version of Busulfex Injection.
read more
Mylan Chairman Robert J. Coury and Chief Executive Officer Heather Bresch provided additional detail regarding the company's efforts to meet public health needs amid the evolving COVID-19 pandemic.
read more
Mylan announced a global collaboration with Gilead Sciences to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19.
read more
Tuesday, September 08, 2020
Mylan announced an agreement to acquire the related intellectual property and commercialization rights of Aspen's thrombosis business in Europe.
read more
Thursday, November 05, 2015
Mylan has announced that the U.S. Federal Trade Commission has cleared the company's proposed transaction to acquire Perrigo Company subject to Mylan's divestiture of certain products following the consummation of the offer.
read more
Mylan lowered the bar for shareholder approval in its ongoing hostile bid for rival pharmaceutical company Perrigo.
read more